Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06118983 · ClinicalTrials.gov registry record · NA

Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)

A NA study of Heart Failure, sponsored by Weill Medical College of Cornell University.

Recruiting
Registry status
NA
Development phase
1,094
Enrollment target
2
Study locations

NCT06118983: Recruiting NA study of Heart Failure, sponsored by Weill Medical College of Cornell University.

NCT06118983 is a NA study of Heart Failure that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 1,094 participants, below the 2,046-participant average among 397 other Heart Failure trials with a reported enrollment target (47% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06118983, a NA study of Heart Failure, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.

RECRUITING
Registry status
NA
Development phase
1,094 participants
Enrollment target
2
Study locations

Study Summary

This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments. The study is interested in two questions: 1. Is I-TRANSFER-HF better than usual care at preventing heart failure patients from returning to the hospital within 30 days? 2. Are there parts of I-TRANSFER-HF that are easy or hard to implement in the real world? The researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.

Primary Outcome

All-cause 30-day hospital readmission among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims

Conditions Studied

Interventions

  • OTHER I-TRANSFER-HF

Study Locations (2)

New York

  • VNS Health Partners in Care - New York
  • Weill Cornell Medicine - New York

Trial Details

FieldValue
Enrollment Target 1,094 participants
Start Date 2026-07-01
Est. Completion 2028-07-01
Phase NA

What NCT06118983 shows while recruiting

NCT06118983 is an interventional study that assigns participants to a tested intervention. Its 1,094 participants enrollment target places it among the larger protocols in the corpus, below the 2,046-participant average among 397 other Heart Failure trials with a reported enrollment target (47% lower).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which I-TRANSFER-HF is the first listed.

NCT06118983 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06118983 about?

NCT06118983 is a clinical study titled "Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)". This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments. The ...

What is the current status of trial NCT06118983?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,094 participants. The study started on 2026-07-01. Estimated completion is 2028-07-01.

What conditions does trial NCT06118983 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT06118983?

The interventions under investigation include: I-TRANSFER-HF (OTHER).

Who is sponsoring clinical trial NCT06118983?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06118983 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06118983's enrollment target sits among peer trials

1,094 65th of 397 higher than 333 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03754114 · 1,094 participants · NA

    Brain Oxygen Optimization in Severe TBI, Phase 3

  • NCT06585241 · 1,094 participants · Phase 4

    A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

  • NCT06191744 · 1,095 participants · Phase 3

    Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

  • NCT07196722 · 1,092 participants · Phase 2

    A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06118983, the US trial registry maintained by the National Library of Medicine. NCT06118983 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.